Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights


- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 –

See the article here:
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Related Posts